Nabriva Therapeutics AG (NBRV) PT Raised to $11 at BofA/Merrill Lynch
Tweet
Share
E-mailGet Alerts NBRV Hot Sheet
Price: $1.42 --0%
Rating Summary:
4 Buy, 6 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Rating Summary:
4 Buy, 6 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Join SI Premium – FREE
BofA/Merrill Lynch raised its price target on Nabriva Therapeutics AG (NASDAQ: NBRV) to $11.00 (from $10.00) while maintaining a Buy rating after the company announced positive LEAP2 results.
Analyst Jason Gerberry notes NBRV is one step closer to potential approval of lefamulin given positive topline and they are raising their probability of success (POS) to 75% (from 70%).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Upgrades STO Express Co Ltd (002468:CH) to Neutral
- Boliden AB (BOL:SS) (BDNNF) PT Raised to SEK2.75 at Morgan Stanley
- Jefferies Upgrades Husqvarna AB (HUSQB:SS) to Buy
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT Change, Hot CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
